Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation

Hepatology Research

Volumn 44, Issue 12, 2014, Pages 1259-1264

  Kawaoka, Tomokazu ^a   Takahashi, Shoichi ^b   Tatsukawa, Yumiko ^a   Hiramatsu, Akira ^a   Hiraga, Nobuhiko ^a   Miki, Daiki ^a   Tsuge, Masataka ^a   Imamura, Michio ^a   Kawakami, Yoshiiku ^a   Aikata, Hiroshi ^a   Ochi, Hidenori ^a   Ishiyama, Kouhei ^c   Ide, Kentaro ^c   Tashiro, Hirotaka ^c   Ohdan, Hideki ^c   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b Department of Gastroenterology Kouyou Nyutaun Hospital   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Hepatitis C virus; Liver transplantation; Telaprevir

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA INTERFERON; CREATININE; CYCLOSPORIN; INTERLEUKIN 28; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; STEROID; TACROLIMUS; TELAPREVIR; URIC ACID; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MALE; RASH; REBOUND; RECURRENT INFECTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TREATMENT DURATION; WILD TYPE;

EID: 84914144388     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12296     Document Type: Article

References (31)

1. Motoda H, Kano Y, Hiragami F, Kawamura K, Matsumoto H. Changes in rupture formation and zonary region stained with Evans blue during the recovery process from aluminum toxicity in the pea root apex. Plant Signal Behav 2011; 6: 98-100.
2. Ochi H, Maekawa T, Abe H et al. IL-28B predicts response to chronic hepatitis C therapy - fine-mapping and replication study in Asian populations. J Gen Virol 2011; 92: 1071-81.
3. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
4. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
5. Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-84.
6. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.
7. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373-83.
8. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-87.
9. Schmidt SC, Bahra M, Bayraktar S et al. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci 2010; 55: 2063-9.
10. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents - a potentially lethal cocktail. Hepatology 2011; 54: 3-5.
11. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-7.
12. Pungpapong S, Aqel BA, Koning L et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700.
13. Tsuge M, Fujimoto Y, Hiraga N et al. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse. PLoS ONE 2011; 6: e23856.
14. Roche B, Sebagh M, Canfora ML et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766-77.
15. Saab S, Oh MK, Ibrahim AB et al. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007; 13: 1032-8.
16. Lodato F, Berardi S, Gramenzi A et al. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol Ther 2008; 28: 450-7.
17. Dinges S, Morard I, Heim M et al. Pegylated interferonalpha2a/ ribavirin treatment of recurrent hepatitis C after liver transplantation. Transpl Infect Dis 2009; 11: 33-9.
18. Kawaoka T, Hiraga N, Takahashi S et al. Achievement of sustained viral response after switching treatment from pegylated interferon alpha-2b to alpha-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report. Intervirology 2012; 55: 306-10.
19. Coilly A, Roche B, Botta-Fridlund D et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience. J Hepatol 2012; 56 (Suppl 2): s21.
20. Kwo P, Ghabril M, Lacerda M et al. Use of telaprevir plus peg interferon/ribavirin for null responders post OLT with advanced fibrosis/cholestatic hepatitis C. J Hepatol 2012; 56 (Suppl 2): S86.
21. McCashland TM, Olivera- Martinez MA, Garcia-Saenz De Sicilia M et al. Early experience with triple drug therapy (telaprevir, pegylated interferon a2A and ribavirin) in patients on cyclosporine A for hepatitis C recurrence after liver transplantation. Liver Transpl 2012; 18: S99.
22. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013; 33 (Suppl 1): 56-62.
23. Fukuhara T, Taketomi A, Motomura T et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-85.
24. Coto-Llerena M, Perez-Del-Pulgar S, Crespo G et al. Donor and recipient IL28B polymorphisms in HCVinfected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 11: 1051-7.
25. Charlton MR, Thompson A, Veldt BJ et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-24.
26. Kawaoka T, Takahashi S, Takaki S et al. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol 2012; 27: 1467-72.
27. Kawaoka T, Hiraga N, Takahashi S et al. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus. Scand J Gastroenterol 2010; 45: 1488-96.
28. Lok AS, Gardiner DF, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.
29. Chayama K, Takahashi S, Toyota J et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-8.
30. Le Pogam S, Yan JM, Chhabra M et al. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrob Agents Chemother 2012; 56: 5494-502.
31. Karino Y, Toyota J, Ikeda K et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58: 646-54.